Combining MDMA with commonly employed, evidence-based cognitive behavioural therapies for trauma is an area of increasing clinical investigation. Founder of Remedy and clinical investigator Dr. Anne Wagner, C.Psych, joins us for a discussion of psychedelic assisted psychotherapy including a MAPS funded trial of Cognitive Processing Therapy (CPT) for PTSD + MDMA that she is currently leading. In this discussion we cover:
Dr. Anne Wagner, C.Psych is the Founder of Remedy, a centre for mental health innovation. Anne’s work focuses on the treatment and prevention of posttraumatic stress disorder, with a particular interest in novel combination interventions such as CBCT + MDMA and CPT + MDMA, as well as understanding and delivering trauma-competent care. She has done significant work with communities affected by HIV, and is particularly interested in the needs of women and interpersonal relationships.Anne is an Adjunct Professor in the Department of Psychology and an Associate Member of the Yeates School of Graduate Studies at Ryerson, and is a trainer in CBCT and consultant for CPT.